.
This is great news for Merck regarding their new HDL-boosting-LDL-busting drug Anacetrapib. Published about a week ago:
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Quote: "The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib."
See also this:
Merck’s Risky Bet on Heart Drugs May Yield Lipitor-Like Success
Interestingly, the company's stock declined by about 5% in November to date.
.
Heavy snowfall forecast for Iceland
-
“Could pose a substantial threat to livestock.” ________________ 19 Sep
2018 – The Iceland Met Office has issued a countrywide yellow weather
warning beg...
1 hour ago
1 comment :
Substance abuse treatment Center turn of the century was the beginning of warp-speed changes at Cenikor. Licensed counselors led the therapeutic community, while Cenikor began to employ business professionals that attended to the administrative functions. Long-term residents began attending colleges and vocational training programs to prepare for life after recovery. Employers became vital business partners.
Post a Comment